UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 469

Sortiert nach

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program

Therapeutic advances in medical oncology, 2021, Vol.13, p.1758835920980558-1758835920980558

2021

Link zum Volltext

Verfügbarkeit prüfen

Stage-Adapted Treatment of HIV-Associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study

Journal of clinical oncology, 2012-11, Vol.30 (33), p.4117-4123

2012

Link zum Volltext

Verfügbarkeit prüfen

Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis

Therapeutic advances in medical oncology, 2022, Vol.14, p.17588359221097191-17588359221097191

2022

Link zum Volltext

Verfügbarkeit prüfen

Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial

Frontiers in oncology, 2024-02, Vol.14, p.1283266-1283266

2024

Link zum Volltext

Verfügbarkeit prüfen

Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancer

Frontiers in oncology, 2023-09, Vol.13, p.1273478-1273478

2023

Link zum Volltext

Verfügbarkeit prüfen

Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP

Data in brief, 2021-02, Vol.34, p.106556-106556, Article 106556

2021

Link zum Volltext

Verfügbarkeit prüfen

“That was a tip from my physician”—Gender‐specific pathways of patients and relatives to outpatient psychosocial cancer counselling centres—A qualitative study

Psycho-oncology (Chichester, England), 2022-06, Vol.31 (6), p.1022-1030

2022

Link zum Volltext

Verfügbarkeit prüfen

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

The Lancet (British edition), 2019-11, Vol.394 (10212), p.1929-1939

2019

Link zum Volltext

Verfügbarkeit prüfen

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

The lancet oncology, 2021-01, Vol.22 (1), p.51-65

2021

Link zum Volltext

Verfügbarkeit prüfen

Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)

Lung cancer (Amsterdam, Netherlands), 2020-12, Vol.150, p.114-122

2020

Link zum Volltext

Verfügbarkeit prüfen

Was Männer davon abhält, ambulante Krebsberatungsstellen aufzusuchen. Eine qualitative Studie

Der Onkologe, 2020-11, Vol.26 (11), p.1047-1055

2020

Link zum Volltext

Verfügbarkeit prüfen

Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors

Journal of oncology pharmacy practice, 2021-07, Vol.27 (5), p.1147-1158

2021

Link zum Volltext

Verfügbarkeit prüfen

What is the best time for psychosocial counselling from the perspective of cancer patients and their relatives? A multi‐centre qualitative study

Counselling and psychotherapy research, 2022-09, Vol.22 (3), p.558-568

2022

Link zum Volltext

Verfügbarkeit prüfen

Das Abenteuer der Erkenntnis: Eine kleine Geschichte des Wissens. Orig.-Ausg

Alt, Jürgen August

2002

Link zum Volltext

Verfügbarkeit prüfen

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Annals of oncology, 2024-01, Vol.35 (1), p.66-76

2024

Link zum Volltext

Verfügbarkeit prüfen

Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer

Oncology research and treatment, 2019-01, Vol.42 (5), p.243-255

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer

Journal of cancer research and clinical oncology, 2018-12, Vol.144 (12), p.2457-2463

2018

Link zum Volltext

Verfügbarkeit prüfen

Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

JTO clinical and research reports, 2024-04, Vol.5 (4), p.100626-100626, Article 100626

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 469

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(231)
Mit Volltextzugriff
(428)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(249)
Deutsch
(238)
Japanisch
(60)
Dänisch
(12)
Spanisch
(1)
Russisch
(1)

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Stage-Adapted Treatment of HIV-Associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study

Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis

Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations

Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial

Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancer

Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP

“That was a tip from my physician”—Gender‐specific pathways of patients and relatives to outpatient psychosocial cancer counselling centres—A qualitative study

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Interim Analysis of a Phase II Study of the GCLLSG and fcgcll/MW

Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)

Was Männer davon abhält, ambulante Krebsberatungsstellen aufzusuchen. Eine qualitative Studie

KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors

Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany

What is the best time for psychosocial counselling from the perspective of cancer patients and their relatives? A multi‐centre qualitative study

Das Abenteuer der Erkenntnis: Eine kleine Geschichte des Wissens. Orig.-Ausg

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer

Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer

Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

P3.02c-091 Final Phase Ib Results of RNActive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC: Topic: IT Clinical

Suchergebnisse filtern